Charles Russell Speechlys advises Biolog-id on the execution of a Business Combination Agreement for proposed $312 million merger
Charles Russell Speechlys Paris has advised Biolog-id on the negotiation of a Business Combination Agreement ("BCA") relating to a proposed merger between Biolog-id and Genesis Growth Tech Acquisition Corp, a Nasdaq-listed special purpose acquisition company ("SPAC").
Biolog-id is a global leader in the development and service of identification and traceability solutions for blood products and injectable therapeutic preparations in oncology. The merger will create a publicly traded digital health solutions company focused on value chain optimisation.
The transaction values Biolog-id at $312 million and is expected to close in the first quarter of 2023. Following the merger, Biolog-id will be listed on Nasdaq under the symbol "BGID”.
Renaud Ferry, Partner, comments: “We are pleased to have advised Biolog-id on a key part of their digital health strategy as they advance their capabilities in value chain optimisation for blood products and other biologics. Our team, based in the Firm’s Paris office, worked alongside a number of law firms across multiple jurisdictions to achieve this result.”
The Charles Russell Speechlys team was led by Partner Renaud Ferry, with support from Associates, Pierre-Adrien Mayot and Orlando Vignoli Neto.
Overall the transaction involved eight firms including Allen & Overy LLP, Linklaters, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Carey Olsen, RSM France, O'Melveny & Myers LLP and Conyers Dill & Pearman LLP, across three jurisdictions.
